Figure 5. The zonulin peptide inhibitor AT-1001 attenuates colonic damage. (A) Sucralose excretion was measured weekly in interleukin 10 gene-deficient (IL10⁻/⁻) mice treated with a high dose of AT-1001 (open squares), low dose (open circles) or placebo (closed circles) from 4 to 17 weeks of age. The data are shown relative to that from wild-type (WT) animals, which is represented in the shaded area. As noted in the text colonic damage becomes evident at 10 weeks of age but is reduced in AT-1001 animals. (B) Statistical analysis of the areas under the curve of sucralose excretion for each group. The sucralose excretion of IL10^−/− mice was significantly higher than that from wild-type animals (*p<0.01). Sucralose excretion of the animals treated with AT-1001 differed significantly from that of the IL10^−/− mice (**p<0.05, n = 10–13), suggesting that AT-1001 reduces but does not prevent colonic damage.